Bristol Myers' Mavacamten Shows Sustained Improvements In Cardiovascular Outcomes In Cardiomyopathy Study

Bristol Myers Squibb Co BMY announced new interim results from the EXPLORER-LTE cohort of the MAVA-LTE study of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM). 

  • The data exhibited sustained improvements in cardiovascular outcomes at 48 and 84 weeks.
  • EXPLORER-LTE enrolled 231 patients. 
  • The safety profile remained consistent with EXPLORER-HCM. No new safety signals were observed during longer-term follow-up, and the exposure adjusted event rates were stable or lower in this cohort.
  • Related: Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy.
  • The resting LVOT gradient decreased from baseline by -35.6 mmHg ± 32.6 mmHg at Week 48. Similar reductions persisted throughout this extension period (up to 84 weeks).
  • Similarly, Valsalva LVOT gradient decreased from baseline by -45.3 mmHg ± 35.9 mmHg at Week 48. Sustained efficacy persisted throughout this extension period (up to 84 weeks).
  • Serum NT-proBNP levels decreased from baseline by a median of -480 ng/L at Week 48. Similar reductions persisted throughout this extension period (up to 84 weeks).
  • Resting LVEF decreased from baseline by -7.0% ± 8.3% at Week 48. A similar level of reduction persisted throughout this extension period (up to 84 weeks).
  • Price Action: BMY shares closed 0.96% lower at $73.11 during after-hours trading on Friday.

Posted In: BriefsBiotechLarge CapNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.